<DOC>
	<DOCNO>NCT02986516</DOCNO>
	<brief_summary>Comparative study surgery versus definitive radiation therapy primary localized sacral chordoma</brief_summary>
	<brief_title>Sacral Chordoma : Surgery Versus Definitive Radiation Therapy Primary Localized Disease</brief_title>
	<detailed_description>International , multicenter , comparative , open-label , parallel-group , mixed Observational-Randomized Controlled Trial . All patient , candidate study receive full information characteristic , potential effectiveness side effect two alternative treatment : radiotherapy ( RT ) surgical treatment Eligible patient ask randomized order receive treatment A ( surgery , without RT ) treatment B ( definitive RT ) Who refuse randomization include Prospective Cohort Study ( PCS ) treat accordingly choice ( treatment option A treatment option B ) . The radiotherapy surgical regimen administer PCS Randomized Clinical Trial ( RCT ) cohort</detailed_description>
	<mesh_term>Chordoma</mesh_term>
	<criteria>Histologically confirm diagnosis ( brachyury expression ) primary sacral chordoma , diameter arise site S1 coccyx . Age≥18years ECOGperformance status ( PS ) 02 No previous antineoplastic therapy Macroscopic tumor detectable MRI/CT scan Patient amenable surgery Patient amenable RT Written inform consent give enrolment , accord International Conference Harmonisation/good clinical practice ( ICH/GCP ) . Distant metastasis Inability maintain treatment position Prior radiotherapy pelvic region Prior therapy sacral chordoma ( include surgery , cryoablation , hyperthermia , etc ) Local condition increase risk RT toxicity ( tumor ulcerate skin infiltration , nonhealing soft tissue infection , fistula treatment field ) Rectal wall infiltration General condition increase risk RT toxicity ( active sclerodermia , xeroderma pigmentosum , cutaneous porphyria ) Presence second active cancer ( exception nonmelanoma skin cancer insitu cervix neoplasia insitu neoplasia ) Severe comorbidities result prognosis le 6 month Inability give inform consent Other malignancy within last 5 year Performance status ≥ 2 ( ECOG ) . Significant cardiovascular disease ( example , dyspnea &gt; 2 NYHA ) Significant systemic disease grade &gt; 3 NCICTCAE v4.03 scale , limit patient availability , accord investigator judgment may contribute significantly treatment toxicity Women pregnant breastfeed Psychological , familial , social geographic circumstance limit patient 's ability comply protocol inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>